GlassScriptPhysician profile
Meredith Butler
NPI 1760715569
$16,442.01
in general payments reported to CMS, 2019-2025
37 companies · $6,502 in 2025
The $6,502 reported for 2025 was more than what 98% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,405 · 2022: $2,166 · 2023: $2,830 · 2024: $3,539 · 2025: $6,502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Consulting Fee: $1,350 · Education: $249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,271.56 |
| Consulting Fee | $1,350.00 |
| Education | $249.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,992.64 | 2021-2025 | |
| Janssen Biotech, INC. | $2,336.53 | 2021-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,721.49 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Qol Medical, LLC | $1,218.28 | 2023-2025 | Sucraid, Sucraid |
| Pfizer INC. | $844.94 | 2022-2025 | |
| Genzyme Corporation | $838.25 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $727.30 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Madrigal Pharmaceuticals | $658.61 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $545.05 | 2022-2025 | Ibsrela |
| Celgene Corporation | $512.40 | 2021-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $499.21 | 2022-2025 | Dupixent |
| Lilly USA, LLC | $292.60 | 2024-2025 | Omvoh |
| Celltrion USA INC. | $220.01 | 2024-2025 | Vegzelma, Zymfentra |
| Medtronic, INC. | $215.00 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $167.02 | 2021-2025 | Iqirvo |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $164.71 | 2023-2025 | Linzess |
| Vivus LLC | $155.79 | 2024-2025 | Pancreaze |
| Aimmune Therapeutics, INC. | $139.02 | 2024-2025 | Zenpep |
| Phadia US INC. | $138.09 | 2021-2025 | Immunocap |
| Phathom Pharmaceuticals, INC. | $135.54 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $126.97 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $104.76 | 2021-2023 | |
| Lucid Diagnostics INC. | $91.98 | 2023-2025 | |
| Ferring Pharmaceuticals INC. | $88.23 | 2021-2025 | Rebyota |
| Actelion Pharmaceuticals US, INC. | $83.60 | 2023 | Uptravi, Opsumit |
| Braintree Laboratories, INC. | $76.35 | 2021-2024 | Sutab, Suflave |
| Intercept Pharmaceuticals, INC. | $48.43 | 2022-2025 | |
| Amgen INC. | $45.64 | 2022-2023 | Amjevita, Avsola |
| Fresenius Kabi USA, LLC | $45.61 | 2023 | Idacio |
| Sandoz INC. | $35.96 | 2023-2024 | Hyrimoz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.50 | 2023 | Cyltezo |
| Shield Therapeutics INC | $34.46 | 2025 | |
| Novo Nordisk INC | $30.08 | 2025 | Wegovy |
| Nestle Healthcare Nutrition INC. | $22.53 | 2022 | |
| Redhill Biopharma INC. | $20.52 | 2021 | |
| Axonics, INC. | $15.88 | 2023 | Bulkamid |
| Alfasigma USA, INC. | $13.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Butler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.